<p>高盛分析师 Corinne Johnson 今天对 Immunovant 维持了持有评级，并设定了 28.00 美元的目标价。</p>
<h3>在 TipRanks Premium 上享受 50% 的折扣，放心投资</h3>
<ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
<p>Johnson 覆盖医疗保健行业，关注的股票包括 Roivant Sciences、Rhythm Pharmaceuticals 和 Halozyme。根据 TipRanks 的数据，Johnson 推荐股票的平均回报率为 7.5%，成功率为 54.07%。</p>
<p>除了高盛，Immunovant 还在今天的报告中获得了 Truist Financial 的 Danielle Brill 的持有评级。然而，在同一天，LifeSci Capital 对 Immunovant（NASDAQ: IMVT）维持了买入评级。</p>

IMVT

<p>高盛分析师 Corinne Johnson 对 Immunovant 维持了持有评级，目标价为 28.00 美元。Johnson 负责医疗保健行业，平均回报率为 7.5%，成功率为 54.07%。Truist Financial 也发布了持有评级，而 LifeSci Capital 则对 Immunovant 维持了买入评级</p>

<p>Goldman Sachs analyst Corinne Johnson maintained a Hold rating on Immunovant today and set a price target of $28.00.</p>
<div class="lb-trans"><p>高盛分析师 Corinne Johnson 今天对 Immunovant 维持了持有评级，并设定了 28.00 美元的目标价。</p>
</div><h3>Claim 50% Off TipRanks Premium and Invest with Confidence</h3>
<div class="lb-trans"><h3>在 TipRanks Premium 上享受 50% 的折扣，放心投资</h3>
</div><ul>
<li>Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions</li>
<li>Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential</li>
</ul>
<div class="lb-trans"><ul>
<li>解锁对冲基金级别的数据和强大的投资工具，帮助您做出更聪明、更精准的决策</li>
<li>通过最新的新闻和分析保持市场领先，使您的投资组合始终处于最大潜力的状态</li>
</ul>
</div><p>Johnson covers the Healthcare sector, focusing on stocks such as Roivant Sciences, Rhythm Pharmaceuticals, and Halozyme. According to TipRanks, Johnson has an average return of 7.5% and a 54.07% success rate on recommended stocks.</p>
<div class="lb-trans"><p>Johnson 覆盖医疗保健行业，关注的股票包括 Roivant Sciences、Rhythm Pharmaceuticals 和 Halozyme。根据 TipRanks 的数据，Johnson 推荐股票的平均回报率为 7.5%，成功率为 54.07%。</p>
</div><p>In addition to Goldman Sachs, Immunovant also received a Hold from Truist Financial’s Danielle Brill in a report issued today. However, on the same day, LifeSci Capital maintained a Buy rating on Immunovant (NASDAQ: IMVT).</p>
<div class="lb-trans"><p>除了高盛，Immunovant 还在今天的报告中获得了 Truist Financial 的 Danielle Brill 的持有评级。然而，在同一天，LifeSci Capital 对 Immunovant（NASDAQ: IMVT）维持了买入评级。</p>
</div>

高盛对 Immunovant (IMVT) 维持持有评级